Risk stratification for opioid analgesia failure in cancer patients using pharmacogenetic markers
- Authors: Khaytovich E.D.1, Shikh E.V.1, Kazakov R.E.2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Scientific Center for Expertise of Medical Products, Ministry of Health of the Russian Federation
- Issue: Vol 32, No 9 (2025)
- Pages: 138-143
- Section: Oncology
- URL: https://journal-vniispk.ru/2073-4034/article/view/368204
- DOI: https://doi.org/10.18565/pharmateca.2025.9.138-143
- ID: 368204
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background: Morphine is the drug of choice for pain relief in cancer patients; however, interindividual variability in drug response limits the effectiveness of standard doses. The introduction of pharmacogenetic approaches allows for personalized selection of opioid therapy, improving its safety and efficacy.
Objective: Evaluation of the association between OPRM1 (rs1799971), COMT (rs4680), CYP2D6 (*4, *10), and ABCB1 (rs1045642) gene polymorphisms and the need for morphine dose titration in palliative cancer patients, taking into account pharmacokinetic and clinical parameters.
Materials and methods: The study included 86 palliative care cancer patients receiving morphine as their primary analgesic. All participants underwent genotyping for the aforementioned polymorphisms. Plasma morphine concentrations were determined using HPLC-MS/MS. Pain was assessed using a visual analog scale (VAS) at three time points. Based on a combination of genetic factors, an integrated genetic risk scale (0–7 points) was developed, reflecting the likelihood of standard dose ineffectiveness.
Results: The analysis showed that in patients with a high score (5-7 points), dose titration was required in 81% of cases, compared to only 5% of those with a low score (0-1 point). A weak relationship between pain severity and steady-state morphine concentration was found, indicating genetically determined resistance. Personalized dosage selection based on the pharmacogenetic profile enabled therapeutic concentrations and clinically significant pain reduction (VAS ≤ 3) to be achieved without excessive drug exposure.
Conclusion: Pharmacogenetic profiling based on OPRM1, COMT, CYP2D6, and ABCB1 analysis predicts the risk of insufficient analgesia with a standard dose of morphine in cancer patients. The developed integrated scale can be used to stratify patients and select the starting dose of opioid therapy, thereby increasing its efficacy and safety.
About the authors
Evgeny D. Khaytovich
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: eukhad@gmail.com
ORCID iD: 0000-0003-2629-9250
Postgraduate Student, Department of Clinical Pharmacology and Propaedeutics of Internal Medicine, Clinical Pharmacologist
Russian Federation, MoscowEvgenia V. Shikh
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: chih@mail.ru
ORCID iD: 0000-0001-6589-7654
Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Clinical Pharmacology and Propaedeutics of Internal Medicine
Russian Federation, MoscowRuslan E. Kazakov
Scientific Center for Expertise of Medical Products, Ministry of Health of the Russian Federation
Email: rustic100@rambler.ru
ORCID iD: 0000-0003-0802-4229
Cand. Sci. (Biol.), Leading Researcher, Scientific Center for Expertise of Medical Products
Russian Federation, MoscowReferences
- Ziegler L., Mulvey M., Blenkinsopp A., et al. Opioid prescribing for patients with cancer in the last year of life: a longitudinal population cohort study. Pain. 2016 Nov;157(11):2445-2451. https://dx.doi.org/10.1097/j.pain.0000000000000656
- Caraceni A., Hanks G., Kaasa S., et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. 2012;13(2):e58–68. https://dx.doi.org/10.1016/s1470-2045(12)70040-2
- Когония Л.М., Волошин В.Г., Когония Л.М. и др. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. Злокачественные опухоли. 2016;4(Спецвыпуск 2):474-485. [Kogoniya L.M., Voloshin V.G., Kogoniya L.M., et al. Practical recommendations for the treatment of chronic pain syndrome in cancer patients. Malignant tumors. 2016;4(Special issue 2):474-485. (In Russ.)].
- Cecchin E., Stocco G. Pharmacogenomics and Personalized Medicine. Genes (Basel). 2020 Jun 22;11(6):679. https://dx.doi.org/10.3390/genes11060679
- Belle D.J., Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008 Jun 1;77(11):1553-60.
- Chen Q., Zhang T., Wang J.F., Wei D.Q. Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab. 2011 Jun;12(5):436-44. https://dx.doi.org/10.2174/138920011795495259
- Хайтович Е.Д., Ших Е.В., Ибрагимов А.Н. и др. Полиморфизм рецепторных и ферментативных генов, ассоциированных с выраженностью анальгетического эффекта морфина у онкологических пациентов паллиативного профиля. Фармакология & Фармакотерапия. 2025;1:42-48. [Khaitovich E.D., Shikh E.V., Ibragimov A.N., et al. Polymorphism of receptor and enzymatic genes associated with the severity of the analgesic effect of morphine in palliative care cancer patients. Pharmacology & Pharmacotherapy. 2025;1:42-48. (In Russ.)]. https://dx.doi.org/10.46393/27132129_2025_1_42–48
- Albaugh M.D., Harder V.S., Althoff R.R., et al. COMT Val158Met Genotype as a Risk Factor for Problem Behaviors in Youth. Journal of the American Academy of Child & Adolescent Psychiatry. 2010;49(8):841–849. https://dx.doi.org/10.1016/j.jaac.2010.05.015
- Oh C.-S., Lee S.-H., Yoo Y.-B., et al. Mu-Opioid Receptor Polymorphisms and Breast Cancer in a Korean Female Adult Population: A Retrospective Study. Journal of Breast Cancer. 2016;19(2):206. https://dx.doi.org/10.4048/jbc.2016.19.2.206
Supplementary files
